8 ???????? 2008 ? ?? 44 ? ????????? ???????? ??????????? ?????????? ?? ???????? ??????? European Association for the Study Tags: Liraglutide View |
Novo Nordisk s repaglinide NovoNorm is an oral antidiabetic agent for the treatment of type 2 diabetes in patients who uncontrolled by diet and exercise Tags: Liraglutide View |
Liraglutide (NN2211), marketed under the brand name Victoza, is a long-acting glucagon-like peptide-1 (GLP-1) analog that has been developed by Novo Nordisk for the treatment of type 2 diabetes. The product was approved by the European Medicines Agency (EMEA) on July 3, 2009, and by the U.S. Food and Drug Administration (FDA) on January 25, 2010.
Liraglutide is marketed under the brandname Victoza in the U.S. and Europe. It has been launched in Germany, Denmark, the Netherlands, the United Kingdom, Ireland, and the United States.
Phase I trials of an oral variant of Victoza (NN9924) are starting in 2010.
Iupac Name: ''L''-histidyl-''L''-alanyl-''L''-?-glutamylglycyl-''L''-threonyl-''L''-phenylalanyl-''L''-threonyl-''L''-seryl-''L''-?-aspartyl-''L''-valyl-''L''-seryl-''L''-seryl-''L''-tyrosyl-''L''-leucyl-''L''-?-glutamylglycyl-''L''-glutaminyl-''L''-alanyl-''L''-alanyl-N6-N-(1-oxohexadecyl)-''L''-?-glutamyl-''L''-lysyl-''L''-?-glutamyl-''L''-phenylalanyl-''L''-isoleucyl-''L''-alanyl-''L''-tryptophyl-''L''-leucyl-''L''-valyl-''L''-arginylglycyl-''L''-arginyl-glycine
Synonyms: Arg34Lys26-(''N''-?-(?-Glu(''N''-?-hexadecanoyl)))-GLP-17-37
Number on List: 204656-20-2
Atc Prefix: A10
Atc Suffix: BX07
C: 172 H=265 N=43 O=51
Molecular Weight: 3751.20 g/mol
Bioavailability: N/A
Elimination Half-life: 11-15 hours
Routes Of Administration: Subcutaneous